Genomics company Pacific Biosciences of California (NASDAQ: PACB) announced better-than-expected revenue in Q3 2026, with sales up 5.5% year on year to $40.56 million. Its non-GAAP loss of $0.11 per share was 16.1% above analysts’ consensus estimates.

Is now the time to buy PACB? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

PacBio’s third quarter demonstrated steady momentum, with management attributing performance to stronger adoption of its SPRQ-Nx chemistry and expanded clinical utilization across key regions. CEO Mark Van Oene pointed to the increasing proportion of consumables revenue coming from clinical markets, now exceeding one-fifth of total business, and highlighted rising Revio and Vega system placements as evidence of customer demand. While the market response was muted, management emphasized that clinical and strategic partnerships—particularly in Europe and China—were the main contributors to growth this quarter.

Looking forward, PacBio’s guidance is anchored by expectations for continued SPRQ-Nx adoption, higher clinical pull-through, and new high-throughput system launches. Van Oene underscored the company’s focus on supporting larger genomic programs and forming foundational data partnerships for biomedical AI. He noted, “We are seeing the earliest work showing signs that PacBio data can participate across the full continuum, from understanding disease, to diagnosing it, to designing therapies.” Management remains cautious about academic and government funding, but sees a robust opportunity in clinical and AI-driven genomics.

Key insights from management’s remarks

Management highlighted the impact of SPRQ-Nx chemistry rollout, strategic partnerships in clinical genomics, and early traction in AI collaborations as central themes for the quarter.

• SPRQ-Nx chemistry adoption: Over half of Revio consumable revenue was generated from customers using SPRQ-Nx, with two-thirds of the install base upgrading software. Management sees this as a key driver of utilization and future pull-through per system.
• Clinical segment growth: Clinical consumables now exceed 20% of overall business and are growing over 20% year-over-year, fueled by new customers and expanded clinical workflows, especially in Europe and China.
• Strategic deals in China: The Berry Genomics partnership for a national rare disease program signals entry into large-scale, long-read clinical sequencing in China, supporting both near-term consumables demand and broader market access.
• AI and data partnerships: Collaborations with Verily Health and TychoBio position PacBio’s HiFi sequencing as foundational for biomedical AI, enabling richer datasets for disease understanding and therapeutic discovery.
• Regional dynamics and funding: EMEA remains the strongest region for system placements and clinical adoption, while capital spending constraints persist in the Americas due to ongoing funding uncertainty. Sequential improvement in Asia-Pacific was driven by China, but Japan and Korea continue to face funding headwinds.

Drivers of future performance

PacBio’s outlook hinges on the ongoing adoption of SPRQ-Nx, expansion of clinical applications, and the successful launch of its high-throughput platform.

• SPRQ-Nx and clinical pull-through: Management expects SPRQ-Nx to drive higher utilization and recurring consumables revenue as customers complete workflow transitions and reorder cycles, with clinical adoption leading future growth.
• High-throughput platform launch: The company is prioritizing R&D resources for its upcoming high-throughput sequencing instrument, scheduled for commercial launch next year, which is expected to enable larger-volume projects and strategic partnerships.
• Macro and funding headwinds: PacBio remains cautious about academic and government funding, particularly in the Americas and parts of Asia, and continues to assume no meaningful recovery in these segments for the near term.

Catalysts in upcoming quarters

In the coming quarters, our team will focus on (1) the pace of SPRQ-Nx adoption and resulting increases in consumables pull-through, (2) milestones in high-throughput platform development and its initial commercial uptake, and (3) continued expansion of strategic partnerships in clinical genomics and AI data collaborations. Execution on cost discipline and evidence of improved capital spending environments in key regions will also be important to monitor.

PacBio currently trades at $2.58, up from $2.55 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).

Stocks that trumped tariffs

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.